Stock Research: West Pharmaceutical Services

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

West Pharmaceutical Services

NYSE:WST US9553061055
88
  • Value
    100
  • Growth
    21
  • Safety
    Safety
    50
  • Combined
    73
  • Sentiment
    80
  • 360° View
    360° View
    88
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

West Pharmaceutical Services, Inc. designs and manufactures containment and delivery systems for injectable drugs. The company operates in the pharmaceutical, diagnostic, and medical device industries. It is a global company. In the last fiscal year, the company had a market cap of $15,881 million, profits of $1 million, and revenue of $3 million, with 10600 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 88 (better than 88% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock West Pharmaceutical Services are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for West Pharmaceutical Services. The consolidated Value Rank has an attractive rank of 50, which means that the share price of West Pharmaceutical Services is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 50% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 100. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 80. But the consolidated Growth Rank has a low rank of 21, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 79 of its competitors have better growth. ...read more

more
Index
Dividends USA
D.J. US Medical Equipment
S&P 500
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
50 48 26 57
Growth
21 12 65 81
Safety
Safety
100 100 93 85
Sentiment
80 56 86 93
360° View
360° View
88 76 89 100
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
71 78 67 36
Opinions Change
58 7 50 91
Pro Holdings
n/a 47 69 69
Market Pulse
69 71 87 72
Sentiment
80 56 86 93
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
50 48 26 57
Growth
21 12 65 81
Safety Safety
100 100 93 85
Combined
73 44 73 95
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
21 18 18 24
Price vs. Earnings (P/E)
23 31 13 31
Price vs. Book (P/B)
22 23 9 14
Dividend Yield
86 84 79 86
Value
50 48 26 57
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
45 54 63 37
Profit Growth
34 18 42 86
Capital Growth
13 9 12 39
Stock Returns
37 22 93 83
Growth
21 12 65 81
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
79 72 64 58
Refinancing
35 20 25 25
Liquidity
100 100 100 98
Safety Safety
100 100 93 85

Similar Stocks

Discover high‑ranked alternatives to West Pharmaceutical Services and broaden your portfolio horizons.

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.